Search Results



Your search for Matthew Stenger matches 2844 pages

Showing 151 - 200


leukemia

Adding Idelalisib to Bendamustine/Rituximab in Relapsed/Refractory CLL

As reported by Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet Oncology, interim analysis of a phase III trial has shown the superiority of adding the phosphoinositide-3-kinase δ inhibitor idelalisib (Zydelig) to bendamustine/rituximab (Rituxan) in...

breast cancer

Interventionist-Guided Weight Loss Program for African American Breast Cancer Survivors

As reported by Stolley et al in the Journal of Clinical Oncology, a community-based interventionist-guided weight loss program for African American breast cancer survivors (Moving Forward) proved successful in achieving weight loss goals compared with a self-guided weight loss program. African...

leukemia

Adding Midostaurin to Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation

In a phase III trial (Cancer and Leukemia Group B 10603 [RATIFY]/Alliance) reported in The New England Journal of Medicine, Stone et al found that the addition of midostaurin (Rydapt) to standard chemotherapy improved overall survival in patients with newly diagnosed acute myeloid leukemia with...

colorectal cancer

First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Advanced Colorectal Cancer

A phase III trial has shown no significant difference in overall survival with first-line cetuximab (Erbitux) vs bevacizumab (Avastin) plus chemotherapy in patients with advanced or metastatic KRAS wild-type colorectal cancer. These study findings were reported by Venook et al in JAMA. The trial...

breast cancer

Study Estimates Risks of Breast and Ovarian Cancers in BRCA1/2-Mutation Carriers

In a prospective cohort study reported in JAMA, Kuchenbaecker et al derived estimates of cumulative risks for breast, ovarian, and contralateral breast cancers among women carrying BRCA1 or BRCA2 mutations. Study Details The study involved data from 6,036 BRCA1 and 3,820 BRCA2 carriers recruited...

head and neck cancer

Outcome by Age With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer

As reported in the Journal of Clinical Oncology by Brose et al, a prespecified analysis of the phase III double-blind SELECT trial of lenvatinib (Lenvima) vs placebo in radioiodine-refractory differentiated thyroid cancer showed progression-free survival benefits in both older and younger...

lung cancer

First-Line Nivolumab vs Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 5%

As reported by Carbone et al in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based chemotherapy in patients with recurrent or stage IV non–small cell lung cancer with...

skin cancer

Dabrafenib Plus Trametinib in BRAF V600–Mutant Melanoma Brain Metastases

A phase II trial has shown that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinst) produces responses in brain metastases in patients with BRAF V600–mutant melanoma. These findings were reported by Davies et al in The Lancet Oncology. Study ...

lymphoma

Brentuximab Vedotin vs Physician’s Choice in CD30-Positive Cutaneous T-Cell Lymphoma

The phase III ALCANZA trial has shown that brentuximab vedotin (Adcetris) produces a higher global response rate vs physician’s choice of therapy in previously treated CD30-positive cutaneous T-cell lymphomas. These results were reported by Prince et al in The Lancet. Study Details In this...

palliative care

Impact of Palliative Care on End-of-Life Services for Patients Dying in a Hospital

In a single-center retrospective analysis reported in the Journal of Oncology Practice, Wiesenthal et al found that among patients dying in a hospital, those with palliative care in place at final admission received less diagnostic testing and other services not associated with promoting patient...

lung cancer

Atezolizumab as First-Line or Subsequent Treatment in PD-L1–Selected Advanced NSCLC

In the phase II BIRCH trial, atezolizumab (Tecentriq) was found to produce higher response rates as first-line or subsequent therapy in patients with advanced non–small cell lung cancer (NSCLC) with higher levels of programmed cell death ligand 1 (PD-L1) expression. Study findings were...

neuroendocrine tumors

177Lu-Dotatate Improves Progression-Free Survival in Advanced Progressive Midgut Neuroendocrine Tumors

In the phase III NETTER-1 trial reported in The New England Journal of Medicine, Jonathan R. Strosberg, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues found that the addition of the targeted radiotherapeutic agent lutetium-177 (177Lu)-Dotatate to the long-acting repeatable...

colorectal cancer

ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers in Colorectal Cancer

As reported in the Journal of Clinical Oncology by Antonia R. Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...

colorectal cancer

Effect of Postdiagnosis Aspirin and Other NSAIDs on Survival in Colorectal Cancer

As reported by Hua et al in the Journal of Clinical Oncology, long-term survivors of colorectal cancer with KRAS wild-type tumors had improved survival with regular use of any nonsteroidal anti-inflammatory drug (NSAID) post diagnosis. The study involved data from 2,149 patients aged 18 to 74...

breast cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Adjuvant Therapy for Breast Cancer

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by...

pancreatic cancer

Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma

In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. John P....

prostate cancer

Testosterone Replacement Therapy and the Risk of Prostate Cancer

In a Swedish study reported in the Journal of Clinical Oncology, Stacy Loeb, MD, of New York University, and colleagues found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among...

survivorship

Decreasing but Still Elevated Risk for Subsequent Neoplasms in Survivors of Childhood Cancer

In a retrospective multicenter cohort study reported in JAMA, Lucie M. Turcotte, MD, MPH, of the University of Minnesota, Minneapolis, and colleagues found that the risk of subsequent neoplasms in 5-year survivors of childhood cancers decreased between those diagnosed in the 1970s vs the 1990s but ...

breast cancer

Equivalence Trial of Neoadjuvant Trastuzumab Biosimilar CT-P6 vs Trastuzumab in HER2-Positive Breast Cancer

A phase III equivalence trial has shown comparable pathologic complete response rates with the proposed trastuzumab biosimilar CT-P6 vs reference trastuzumab (Herceptin) in neoadjuvant treatment of HER2-positive early breast cancer. The study was reported by Stebbing et al in The Lancet Oncology....

palliative care

Effect of Embedding Palliative Care in an Oncology Clinic

A retrospective analysis reported in the Journal of Oncology Practice by Einstein et al showed the benefits of embedding palliative care in a clinic specializing in targeted and immune-based treatments in patients with melanoma or renal cancer. Study Details The study included data from 114...

breast cancer

Trends in Surgery After Initial Lumpectomy for Breast Cancer

In a study reported in JAMA Oncology, Morrow et al found that the rates of surgery after initial lumpectomy for stage I or II breast cancer have decreased with dissemination of guidelines advocating a minimal negative surgical margin. A 2014 consensus statement of the Society of Surgical Oncology...

multiple myeloma
cost of care

Impact of Subsidies on Use of Oral Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

According to a study by Olszewski and colleagues in the Journal of Clinical Oncology, Medicare Part D beneficiaries without a low-income subsidy may face daunting barriers in affording oral immunomodulatory drugs for myeloma. The low-income subsidy markedly reduces out-of-pocket costs for...

lung cancer

Ceritinib vs Chemotherapy in Previously Treated ALK-Rearranged NSCLC

The phase III ASCEND-5 trial has shown a significant improvement in progression-free survival with ceritinib (Zykadia) vs chemotherapy in advanced ALK-rearranged non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori) and chemotherapy. Trial results were reported in...

gastroesophageal cancer

High-Dose First-Line Trastuzumab Maintenance in Metastatic HER2-Positive Gastric Cancer

As reported in the Journal of Clinical Oncology by Shah et al, the phase IIIB HELOISE trial has shown no survival benefit of high-dose vs standard trastuzumab (Herceptin) maintenance plus chemotherapy in the first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma....

gynecologic cancers

Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis

A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...

breast cancer

Combination of Buparlisib and Fulvestrant in Postmenopausal Women With Advanced Breast Cancer

In the phase III BELLE-2 trial, the addition of the PI3K inhibitor buparlisib to fulvestrant (Faslodex) improved progression-free survival in postmenopausal hormone receptor–positive, HER2-negative advanced breast cancer—but at the cost of excessive toxicity. Results were reported in...

solid tumors

Pembrolizumab in Solid Tumors With Mismatch-Repair Deficiency

As reported by Le et al in Science, pembrolizumab (Keytruda) was found to be active across a range of solid tumors with mismatch-repair (MMR) deficiency. Pembrolizumab was recently approved for treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or...

gastroesophageal cancer

Association of EGFR Copy Number Gain and Outcome With Gefitinib in Advanced Esophageal Cancer

As reported by Petty et al in the Journal of Clinical Oncology, analysis of outcomes in the UK phase III Cancer Esophagus Gefitinib trial showed an overall survival benefit with second-line gefitinib (Iressa) in patients with advanced esophageal cancer who had epidermal growth factor receptor...

breast cancer

Adding Abemaciclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

In the phase III MONARCH 2 trial reported at the recent ASCO Annual Meeting and in the Journal of Clinical Oncology by Sledge et al, the addition of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib to fulvestrant (Faslodex) improved progression-free survival in hormone...

lung cancer

Sacituzumab Govitecan in Previously Treated Patients With Metastatic NSCLC

As reported by Heist et al in the Journal of Clinical Oncology, the antibody-drug conjugate sacituzumab govitecan showed activity in patients with previously treated metastatic non–small cell lung cancer (NSCLC). Sacituzumab targets Trop-2, present on many solid tumors; govitecan is the...

skin cancer

Melanoma-Specific Survival With Completion Dissection vs Observation for Sentinel Node Metastasis

The phase III MSLT-II trial showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel node metastasis, although a benefit was observed in regional disease control. The findings were reported in The New England...

leukemia

Clofarabine-Based Consolidation in Younger Patients With AML

In a French randomized phase II trial reported in the Journal of Clinical Oncology, Thomas et al found that clofarabine-based consolidation may provide improved relapse-free survival vs conventional high-dose cytarabine in postremission treatment in younger patients with acute myeloid leukemia...

breast cancer

Anthracyclines in HER2-Negative Breast Cancer

As reported by Joanne L. Blum, MD, PhD, of Baylor University Medical Center, Texas Oncology, and colleagues in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane ...

prostate cancer

Ipilimumab vs Placebo in Metastatic Chemotherapy-Naive, Castration-Resistant Prostate Cancer Without Visceral Metastases

In the phase III CA184-095trial reported in the Journal of Clinical Oncology, Tomasz M. Beer, MD, FACP, of the Knight Cancer Institute, Oregon Health and Science University, and colleagues found that ipilimumab (Yervoy) did not increase overall survival vs placebo in men with asymptomatic or...

prostate cancer

Survival Benefit of Adding Antiandrogen Therapy to Radiation in Recurrent Prostate Cancer: Final Results of RTOG 9601

As reported in The New England Journal of Medicine by W.U. Shipley, MD, of Massachusetts General Hospital and Harvard Medical School, and colleagues in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial shows that the addition of...

lung cancer

Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer

In the phase III OAK trial reported in The Lancet by Achim Rittmeyer, MD, of Lungenfachklinik Immenhausen, Germany, and colleagues, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small ...

multiple myeloma

Lenalidomide, Bortezomib, and Dexamethasone With or Without Transplantation in Younger Myeloma Patients

In the French phase III IFM 2009 trial reported in The New England Journal of Medicine by Michel Attal, MD, of the Institut Universitaire du Cancer de Toulouse-Oncopole, and colleagues, consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was...

lung cancer

Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.  On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...

lung cancer

ALEX Trial: Alectinib vs Crizotinib in Untreated Advanced ALK-Positive NSCLC

As reported at the recent ASCO Annual Meeting and in The New England Journal of Medicine by Peters et al, the phase III ALEX trial has shown improvement in progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in the first-line treatment of advanced ALK-positive...

gynecologic cancers

Tumor Microvessel Density and Outcome With Bevacizumab in Ovarian Cancer

A retrospective biomarker analysis of the phase III GOG-0218 trial indicated a higher tumor microvessel density was associated with progression-free and overall survival benefit with bevacizumab (Avastin) vs placebo plus front-line chemotherapy in patients with ovarian cancer. These findings were...

cns cancers

Dinutuximab vs Temsirolimus in Combination Therapy for Children With Refractory or Relapsed Neuroblastoma

A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab (Unituxin) plus irinotecan/temozolomide as a regimen to be further evaluated in the treatment of pediatric patients with refractory or relapsed neuroblastoma. Study results were ...

prostate cancer

T2:ERG and PCA3 RNA Urinary Testing for Detecting Aggressive Prostate Cancer

Combined testing for urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA may increase accuracy in identifying the risk for aggressive early prostate cancer, according to a study reported in JAMA Oncology by Sanda et al in the EDRN-PCA3 Study Group. Study Details The study involved 516 development cohort...

lung cancer

Effect of Previous Radiotherapy on Outcome With Pembrolizumab in NSCLC

In a single-site experience reported in The Lancet Oncology by Shaverdian et al, patients with advanced non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial of pembrolizumab (Keytruda) were found to have better outcomes if they had received prior radiotherapy. Study Details...

breast cancer

OlympiAD Trial: Olaparib in Metastatic Breast Cancer With Germline BRCA Mutation

As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Robson et al, the phase III OlympiAD trial showed that the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) prolonged progression-free survival vs standard therapy in...

prostate cancer

LATITUDE Trial: Adding Abiraterone and Prednisone to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer

As reported in a Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Fizazi et al, the phase III LATITUDE trial has shown that the addition of abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy resulted in marked improvements in...

issues in oncology

Twitter Use at the ASCO Annual Meeting

As reported by Pemmaraju et al in the Journal of Oncology Practice, use of Twitter at the ASCO Annual Meeting has increased dramatically between 2011 and 2016. The investigators conducted a retrospective review of publicly available tweets collected by Nephrology On-Demand Analytics for the ASCO...

multiple myeloma

Spanish Analysis of Prognostic Impact of MRD-Negative Status in Multiple Myeloma

A pooled analysis of three PETHEMA/GEM studies has shown that minimum residual disease (MRD)-negative status after induction therapy is more prognostic of favorable outcome than complete response alone in newly diagnosed multiple myeloma. The findings were reported by Lahuerta et al in the Journal...

lung cancer

Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC

The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...

breast cancer

Breast Cancer Risk and Histologic Findings in Serial Benign Biopsies

As reported by Visscher et al in the Journal of the National Cancer Institute, changes in the histologic category between initial and subsequent biopsies had a significant effect on the risk for breast cancer among women with serial benign biopsy findings. Study Details The study involved 1,414...

prostate cancer

Clinical Implications of Luminal and Basal Subtyping of Prostate Cancer

As reported by Zhao et al in JAMA Oncology, luminal B prostate cancers carry a worse overall prognosis than luminal A and basal-like cancers, but luminal B tumors respond better to postoperative androgen-deprivation therapy. Study Details In the study, the PAM50 classifier was used to subtype...

Advertisement



Advertisement


Advertisement